A First in Human, Single-dose Escalation Study of LY2562175 In Healthy Subjects

Completed

• Conditions: lipids; metabolism; 10013317

• Registration Number: NL-OMON33901
• Lead Sponsor: Chorus, Lilly Research Laboratories

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

Healthy men or women of non child bearing potential
18 - 60 years inclusive

Exclusion Criteria

18 - 60 years inclusive
BMI 18 - 30 kg/m
By screening no abnormalities found

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics:<br /><br>plasma LY2562175 concentrations, pharmacokinetic parameters<br /><br><br /><br>Safety:<br /><br>adverse events, vital signs, ECG-parameters, laboratory parameters, physical<br /><br>examination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Pharmacodynamics :<br /><br>bile acid panel, fasting lipid panel (TG, LDL-C, VLDL-C, directed HDL, HDL-C<br /><br>and TC) and target engagement as measured by changes in TG, LDL-C and HDL-C.</p><br>